Andreas Serra holds an MD and MPH degree, trained at the University of Bern, University of Alabama in Birmingham and in Boston at the Harvard University. Prof. Serra has completed a postdoctoral fellowship at the Harvard School of Public Health. He is the head of the SUISSE ADPKD (Therapies for autosomal dominant polycystic kidney disease) cohort and co-director of the Swiss TSC (Treatment for Tuberous Sclerosis) network.
- Mammalian target of rapamycin (mTOR) signaling pathway
- Therapies for autosomal dominant polycystic kidney disease (ADPKD)
- Treatment for Tuberous Sclerosis (TSC)